Building an exciting pipeline

Rejuvenate Biomed One Pager

Highlights

Positive results Phase 1b trial in sarcopenia

Primary and secondary endpoints have been met in this placebo-controlled study in disuse-induced muscle atrophy. RJx-01 was safe and well tolerated and the innovative formulation confirmed excellent pharmacokinetics.

LEARN MORE

Publication of animal data on RJx-01

Data published in JCI Insight show that RJx-01 significantly increases muscle mass, muscle strength and physical performance in sarcopenia mouse models.

LEARN MORE

Advisory Board endorses clinical Ph 2b strategy

Rejuvenate Biomed organized a Clinical Advisory Board meeting to discuss the clinical development of lead candidate RJx-01 in sarcopenia.

LEARN MORE

Committed to a sustainable future

After identifying 5 core Sustainable Development Goals, Rejuvenate Biomed defined company actions to reach these goals for a sustainable future.

LEARN MORE

Clinical-stage biotech dedicated to the discovery and development of therapeutics to delay the onset of multiple age-related diseases

Building an exciting pipeline

Highlights

Positive results Phase 1b trial in sarcopenia

Publication of animal data on RJx-01

Advisory Board endorses clinical Ph 2b strategy

Committed to a sustainable future

Acknowledgements and investors

Clinical-stage biotech dedicated to the discovery and development of therapeutics
to delay the onset of multiple age-related diseases